Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

ctively, based on weighted average shares outstanding of 17.6 million and 17.5 million, respectively.

Cash equivalents and short-term investments were approximately $57.0 million at September 30, 2009, compared to $13.4 million at June 30, 2009. The increase reflects the receipt of a $48.8 million upfront payment from Astellas received in July 2009.

Stephen Ghiglieri, CFO, commented, "The third quarter of 2009 represents the first time we have reported quarterly revenue, which marks a milestone for NeurogesX. Our balance sheet is also strongly positioned with $57 million in cash, cash equivalents and short term investments. Consistent with our spending guidance for 2009, we are continuing our conservative focus in advance of our upcoming PDUFA date. As a result of that focus, we have been investing in commercialization activities that require long lead times, such as setting up the distribution channel, that are necessary to implement now to be ready for our targeted first half 2010 launch. Major investments, such as sales force deployment, are still being deferred pending FDA approval of Qutenza. We are also exploring strategies to further strengthen our balance sheet ahead of a potential U.S. Qutenza launch."

Development Update

NeurogesX is advancing its planning for NGX-1998 and expects to re-initiate clinical development activities in 2010.

Conference Call Details

The Company will hold its quarterly conference call today at 9:00 a.m. ET (6:00 a.m. PT) to discuss third quarter 2009 results.

To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). To access the live web cast please visit the Investor Relations section on the corporate web site at http://www.neurogesx.com.

A replay of the conference call will be available beginning November 6, 2009 at 7:30 p.m. ET (4:30 p.m. PT) and endi
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... All amounts are in U.S. dollars , , ... 13 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( AEZS, TSX: AEZ) ("the Company"), a late-stage ... at and for the three months ended March 31, 2010 . , ... First Quarter 2010 Highlights , , - January 25, 2010: ...
... BIRMINGHAM, Ala. , May 12 Atherotech Inc. will ... Association (NLA) Scientific Sessions 2010. The meeting takes place May 13-16 ... , , ... only advanced lipid test that routinely reports directly measured LDL-C, which is ...
... /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex:, NBS ) ("NeoStem" or the "Company"), an international biopharmaceutical ... at the NASDAQ MarketSite in Times Square, New York City . , ... NeoStem,s CEO, Dr. Robin Smith will provide ... , , ...
Cached Biology Technology:Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 2Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 3Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 4Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 5Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 6Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 7Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 8Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting 2Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting 3NeoStem, Inc. to Present at NASDAQ MarketSite 2NeoStem, Inc. to Present at NASDAQ MarketSite 3
(Date:4/22/2014)... 22, 2014) Biotechnology scientists must be aware of ... and licensing guidelines, according to a new paper from ... in the current issue of the journal Regenerative ... 2013 U.S. Supreme Court ruling in the case Association ... occurring genes are unpatentable. The court case and rulings ...
(Date:4/22/2014)... PETA International Science Consortium Ltd.,s nanotechnology expert will present ... nanomaterial hazard assessment" at the 7th International Nanotoxicology ... Antalya, Turkey. , Dr. Monita Sharma will outline ... US National Academy of Sciences, " Toxicity Testing in ... which recommends use of non-animal methods involving human cells ...
(Date:4/22/2014)... Beaumont Health System with prestigious, competitive research grants ... and nonathletic injuries. , The American Orthopaedic ... to fund stem cell-based research that could help ... knee anterior cruciate ligament, or ACL. According to ... ligament injury is the over-stretching or tearing of ...
Breaking Biology News(10 mins):New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3Beaumont awarded grants to study sports-related injury treatment, improve recovery 2
... RNA component units called ribonucleotides become embedded in genomic ... organism, they can cause problems for cells. It is ... DNA double helix, resulting in genomic instability and altered ... fate of these ribonucleotides. A new study provides ...
... UCLA life scientists and colleagues have produced the ... health of populations exposed to environmental change. ... Foundation, is published Dec. 2 in the journal ... projection model, or IPM, unites various sub-disciplines of population ...
... Most of us would agree that prevention is better than ... Rehabilitation , published by SAGE, indicate that a costly intervention ... Finland had no measurable effect. , The research was a ... participants and their 2440 matched controls for up to nine ...
Cached Biology News:Study identifies mechanisms cells use to remove bits of RNA from DNA strands 2Powerful mathematical model greatly improves predictions for species facing climate change 2Powerful mathematical model greatly improves predictions for species facing climate change 3Costly intervention program has no measurable effect on early retirement 2Costly intervention program has no measurable effect on early retirement 3
Animal Origin Free...
IHC Detection Kit (Broad Spectrum AEC)....
...
... Modification Services ,,GenScript offers many ... and antibody fragmentation. Labeling antibodies with ... visualization and quantitation of the target ... preferable to use only the antigen-binding ...
Biology Products: